Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

iSpecimen (ISPC) EBITDA: 2020-2025

Historic EBITDA for iSpecimen (ISPC) over the last 6 years, with Sep 2025 value amounting to -$2.8 million.

  • iSpecimen's EBITDA fell 93.12% to -$2.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$11.5 million, marking a year-over-year decrease of 23.71%. This contributed to the annual value of -$12.5 million for FY2024, which is 12.61% down from last year.
  • As of Q3 2025, iSpecimen's EBITDA stood at -$2.8 million, which was down 165.52% from -$1.0 million recorded in Q2 2025.
  • In the past 5 years, iSpecimen's EBITDA ranged from a high of -$942,644 in Q1 2021 and a low of -$6.0 million during Q4 2024.
  • Its 3-year average for EBITDA is -$2.7 million, with a median of -$2.5 million in 2023.
  • In the last 5 years, iSpecimen's EBITDA tumbled by 244.27% in 2021 and then surged by 50.35% in 2025.
  • Over the past 5 years, iSpecimen's EBITDA (Quarterly) stood at -$2.0 million in 2021, then fell by 7.35% to -$2.1 million in 2022, then tumbled by 34.06% to -$2.9 million in 2023, then plummeted by 110.62% to -$6.0 million in 2024, then slumped by 93.12% to -$2.8 million in 2025.
  • Its last three reported values are -$2.8 million in Q3 2025, -$1.0 million for Q2 2025, and -$1.7 million during Q1 2025.